Literature DB >> 24102420

Improvement in precision of counting actinic keratoses.

K C Lee1, R Lew, M A Weinstock.   

Abstract

BACKGROUND: Actinic keratoses (AKs) often serve as a primary endpoint for clinical studies. However, reliability of counting these lesions is poor, even among expert dermatologists.
OBJECTIVES: To investigate the reliability of counting AKs before and after a yearly consensus meeting, held annually for 4 years.
METHODS: As part of the Veterans Affairs (VA) Keratinocyte Carcinoma Chemoprevention Trial, board-certified dermatologists convened annually for 4 years to individually count the number of actinic keratoses on three to five test subjects. The dermatologists then met as a group for a consensus discussion on what constituted an AK lesion on each subject. Afterwards, each dermatologist repeated the independent counting exercise on three to five new subjects. The intraclass correlation coefficient (ICC) was used to analyze the reliability of counting AKs among the dermatologists.
RESULTS: Eight dermatologists participated in this exercise for 4 consecutive years. Pre-consensus discussion ICCs over 4 years were 0.18, 0.34, 0.38, 0.75, respectively, showing sustained improvement with each consensus discussion. The greatest improvement in reliability of AK counts was shown during the first year of consensus discussions, when the ICC improved from 0.18 to 0.67. There was no improvement by the fourth year of consensus discussion, with pre- and post-consensus ICCs of 0.75 and 0.75, respectively.
CONCLUSIONS: Annual consensus discussions can lead to improvement in reliability of AK counts. This improvement was sustained over 4 years. By the fourth year, the discussion meeting had no effect on improvement in reliability. A consensus meeting discussion may be helpful for improving reliability in other trials. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Year:  2014        PMID: 24102420     DOI: 10.1111/bjd.12629

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.

Authors:  Martin A Weinstock; Soe Soe Thwin; Julia A Siegel; Kimberly Marcolivio; Alexander D Means; Nicholas F Leader; Fiona M Shaw; Daniel Hogan; David Eilers; Susan M Swetter; Suephy C Chen; Sharon E Jacob; Erin M Warshaw; George P Stricklin; Robert P Dellavalle; Navjeet Sidhu-Malik; Nellie Konnikov; Victoria P Werth; Jonette E Keri; Leslie Robinson-Bostom; Robert J Ringer; Robert A Lew; Ryan Ferguson; John J DiGiovanna; Grant D Huang
Journal:  JAMA Dermatol       Date:  2018-02-01       Impact factor: 10.282

2.  Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015.

Authors:  Howa Yeung; Marissa L Baranowski; Robert A Swerlick; Suephy C Chen; Jennifer Hemingway; Danny R Hughes; Richard Duszak
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

3.  Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL).

Authors:  Kelly Vis; Rick Waalboer-Spuij; Dyon G C T M Snels; Loes M Hollestein
Journal:  Dermatology       Date:  2018-06-15       Impact factor: 5.366

4.  Automated detection of actinic keratoses in clinical photographs.

Authors:  Samuel C Hames; Sudipta Sinnya; Jean-Marie Tan; Conrad Morze; Azadeh Sahebian; H Peter Soyer; Tarl W Prow
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

5.  Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).

Authors:  Zeeshaan-Ul Hasan; Ikhlaaq Ahmed; Rubeta N Matin; Victoria Homer; John T Lear; Ferina Ismail; Tristan Whitmarsh; Adele C Green; Jason Thomson; Alan Milligan; Sarah Hogan; Vanessa Van-de-Velde; Liza Mitchell-Worsford; Jonathan Kentley; Claire Gaunt; Yolande Jefferson-Hulme; Sarah J Bowden; Piers Gaunt; Keith Wheatley; Charlotte M Proby; Catherine A Harwood
Journal:  Br J Dermatol       Date:  2022-06-14       Impact factor: 11.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.